Learning about Lung Cancer

Lung cancer is the most common form of cancer and cause of cancer death globally, accounting for about one-fifth of all cancer deaths. Lung cancer is broadly split into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with 80-85% classified as NSCLC.
As such, AstraZeneca is prioritising lung cancer research to address the significant unmet need for treatments at every stage of the disease continuum. AstraZeneca has a comprehensive portfolio of approved and potential new medicines in late-stage clinical development for the treatment of different forms of lung cancer spanning several stages of disease, lines of therapy and modes of action.
-----------------
Global site: www.astrazenec...
Careers site: careers.astraz...
Follow us:
Twitter: / astrazeneca
LinkedIn: / astrazeneca
Instagram: / astrazeneca
Facebook: / astrazeneca